ABSTRACT
INTRODUCTION: Filgrastim is used for the mobilization of stem cells in healthy donors. Though several biosimilar filgrastim products have been approved, there is limited literature evaluating biosimilar products for stem cell mobilization. Therefore, we conducted this study to compare the effectiveness of the original filgrastim, Neupogen®, to the biosimilar product, Nivestim®, for stem cell mobilization(SCM) in healthy donors. METHODS: This was a retrospective study that included all healthy donors: adults and pediatrics, who received Neupogen® or Nivestim® for stem cell mobilization between 2014 and 2016 at a comprehensive cancer center. Donors received filgrastim at a dose of 5â mcg/kg every 12â h for 4 days to achieve the target CD34 + cell count of 5-10 × 106 CD34 + /kg of recipient body weight. Additional doses of filgrastim were administered and/or the dose increased if target CD34 + was not achieved. The primary endpoint was the number of doses required to achieve the target CD34 + cell count. RESULTS: Over the study period, 89 donors received Neupogen® and 68 received Nivestim®. The median age of donors was 19.5 years (3-64) in the Nivestim® group and 15 years (2-16) in the Neupogen® group. The median number of doses required for SCM was eight doses (6-10) in the Nivestim group and eight (6-16) in the Neupogen® group. CONCLUSION: Biosimilar Nivestim® was as effective as the original, Neupogen®, for stem cell mobilization for healthy adult and pediatric donors. Larger randomized studies are necessary to evaluate the safety and transplant outcomes of the use of Nivestim®.
ABSTRACT
Haploidentical hematopoietic cell transplantation (HCT) is a valuable curative option for children with non-malignant diseases. Haploidentical HCT using post-transplant cyclophosphamide (PTCy) is a readily available option in the absence of an HLA-matched donor. We conducted a retrospective single-center study on the outcome of haploidentical HCT in children with non-malignant diseases. We gathered data from 44 patients underwent HCT in the period 2015 to 2020. The indications for HCT were bone marrow failure, primary immunodeficiency, metabolic disorders, and hemoglobinopathy. Median age at HCT was 4 years (range 0.7-20). The conditioning regimens were myeloablative (n = 17) or reduced intensity (n = 27). After a median follow-up of 20 months (range 4-71), 2-year overall survival was 89% and 2-year GvHD-free relapse-free survival (GRFS) was 66%. Incidence of primary graft failure was 13.6%. Cumulative incidence of grade II-IV acute and moderate/severe chronic GvHD were 20% and 6.4%, respectively. Younger age at HCT (< 4 years) and primary immunodeficiency were significantly associated with better GRFS (p < 0.05). In conclusion, haploidentical HCT using PTCy is feasible and curative in children with non-malignant diseases lacking an HLA-matched donor. Early diagnosis and referral in addition to timely treatment can further improve outcomes.
Subject(s)
Cyclophosphamide/therapeutic use , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/therapeutic use , Transplantation, Haploidentical , Adolescent , Adult , Child , Child, Preschool , Female , Graft vs Host Disease , Hematologic Diseases/therapy , Humans , Infant , Male , Metabolic Diseases/therapy , Primary Immunodeficiency Diseases/therapy , Retrospective Studies , Young AdultABSTRACT
BACKGROUND: Pneumocystis carinii pneumonia (PCP) prophylaxis is recommended after hematopoietic stem cell transplantation (HSCT). In patients who are unable to take first-line prophylaxis, trimethoprim/sulfamethoxazole, aerosolized pentamidine is recommended. This drug may not, however, be available at all institutions, and its administration requires special techniques. Therefore, intravenous pentamidine (IVP) has been used in adult patients as an alternative, despite limited data. We evaluated the effectiveness and tolerability of IVP for PCP prophylaxis in adult patients who had undergone HSCT. METHODS: A single-center retrospective study was conducted of adult patients who had undergone allogenic or autologous HSCT between January 2014 and September 2018 and had received at least three doses of IVP for PCP prophylaxis. The IVP dose was 4 mg/kg administered monthly. Data on PCP infection and adverse reactions were collected from both patients' electronic medical records and the pharmacy adverse drug reactions documentation system. Patients were followed from the start of IVP up to 6 months after discontinuation of therapy. A confirmed PCP infection was defined as radiographic evidence of PCP and positive staining of a respiratory specimen. Descriptive statistics were used to analyze the study outcomes. RESULTS: During the study period, 187 patients were included. The median age was 36.4 years (range, 18-64), 58% were male, and 122 (65%) had received allogeneic HSCT while the remainder autologous HSCT. The median number of IVP doses administered per patient was 5 (range, 3-29). During the study period, none of the patients had evidence of confirmed PCP infection. However; there were two cases with high clinical suspicion of PCP infection (i.e. required anti-pneumocystis therapy) and one reported case of central nervous system toxoplasmosis while receiving IVP for PCP prophylaxis. Only one case of nausea associated with IVP administration was reported. CONCLUSIONS: In a cohort of adult patients with HSCT who received IVP for PCP prophylaxis, there was no evidence of confirmed PCP infection, and the treatment appeared to be well tolerated. Prospective studies should be conducted to confirm the efficacy and tolerability of IVP.
Subject(s)
Antifungal Agents/therapeutic use , Pentamidine/therapeutic use , Pneumonia, Pneumocystis/prevention & control , Adolescent , Adult , Antifungal Agents/adverse effects , Antifungal Agents/pharmacology , Comorbidity , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infusions, Intravenous , Male , Middle Aged , Pentamidine/adverse effects , Pentamidine/pharmacology , Pneumocystis carinii/drug effects , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/microbiology , Retrospective Studies , Transplantation, Autologous , Transplantation, Homologous , Young AdultABSTRACT
INTRODUCTION: Patients with Fanconi anemia have an increased susceptibility to malignancies associated with human papillomavirus, and thus prevention and early management of human papillomavirus infections in this patient population are crucial. CASE REPORT: A nine-year-old girl with Fanconi anemia developed genital warts about three years after undergoing haplo-identical stem cell transplant. The transplant was complicated by chronic graft-versus-host disease, and the patient had therefore received multiple immunosuppressants. The genital warts were treated with several creams, but minimal improvement was reported. MANAGEMENT AND OUTCOME: Cidofovir was extemporaneously compounded into an unscented 1% moisturizing cream and applied daily at bedtime to the genital warts. By the end of treatment, the warts had been successfully treated, and no adverse events were reported. The patient is still free of any lesions at six months after completing treatment. DISCUSSION: Although reports have been published on the use of cidofovir cream, most were in adults with non-genital warts. Cidofovir cream may be considered as a treatment option for refractory genital warts in pediatric patients. However, further studies are needed to better define the optimal preparation and dosing for such patient population.
Subject(s)
Antiviral Agents/administration & dosage , Cidofovir/administration & dosage , Condylomata Acuminata/drug therapy , Fanconi Anemia/drug therapy , Skin Cream/administration & dosage , Child , Condylomata Acuminata/complications , Condylomata Acuminata/diagnosis , Fanconi Anemia/complications , Fanconi Anemia/diagnosis , Female , Humans , Treatment OutcomeABSTRACT
Bacterial infection is a serious sequela following AHSCT; however, limited data are available regarding pediatric recipients, especially in developing countries. We retrospectively analyzed the incidence and risk factors of bacterial infections during the first 100 days after AHSCT in children at KHCC in Amman, Jordan between January, 2005 and September, 2013. A total of 65 patients were identified, with median age of four yr (1-17). Forty-seven patients (72.3%) had solid tumors and 18 (27.7%) had lymphoma. Bacterial infections were documented in 33 patients (50%), with a total of 63 episodes. Gram-negative infection (57.1%) was more prevalent than Gram-positive infection (38%). The risk of bacterial infections was higher among patients less than five yr of age (p = 0.028) and those who developed hypogammaglobulinemia requiring IVIG replacement (p = 0.001). Patients with solid tumors developed more bacterial infections compared to patients with lymphoma (p = 0.0057). No deaths were attributed to bacterial infection. Bacterial infection rate is high among recipients of AHSCT in Jordan with Gram-negative bacteria being the most common.
Subject(s)
Bacterial Infections/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Adolescent , Bacterial Infections/diagnosis , Bacterial Infections/epidemiology , Child , Child, Preschool , Female , Humans , Incidence , Infant , Jordan , Male , Retrospective Studies , Risk Factors , Transplantation, AutologousABSTRACT
There are limited data on the incidence of CMV reactivation following autologous HSCT (AHSCT) in children. We retrospectively reviewed the incidence and risk factors for CMV reactivation in 72 children who received AHSCT. Twenty-two patients (31%) had positive CMV antigenemia at a median of 23 days (12-31) following transplant. Four patients (6%) required preemptive therapy and all episodes resolved. None of the patients developed CMV disease. Only being CMV seropositivity prior to transplant was significantly associated with CMV reactivation (P < 0.001). The incidence of CMV reactivation following pediatric AHSCT is low, and surveillance beyond 30 days is not needed.
Subject(s)
Cytomegalovirus Infections/etiology , Cytomegalovirus/physiology , Hematopoietic Stem Cell Transplantation/adverse effects , Virus Activation , Adolescent , Adult , Child , Child, Preschool , Cytomegalovirus Infections/epidemiology , Female , Humans , Incidence , Infant , Male , Retrospective Studies , Risk Factors , Transplantation, AutologousABSTRACT
BACKGROUND: Patients with thalassemia in developing countries have limited access to safe transfusions, regular medical care and chelation therapy. Although allogeneic hematopoietic stem cell transplantation (HSCT) can offer a curative approach, there are limited data on the use of this procedure in developing countries. PROCEDURE: Forty-four patients underwent a risk adopted HSCT from matched related family donor in Jordan. Thirty-one patients (7 Class 1 and 24 Class 2) underwent myeloablative conditioning (MAC) with busulfan (16 mg/kg), cyclophosphamide (200 mg/kg) and antithymocyte globulin (ATG). Thirteen patients all with Class 3, seven with hepatitis C received reduced intensity conditioning (RIC) with busulfan (8 mg/kg), fludarabine (175 mg/m(2)), total lymphoid irradiation (500 cGy) and ATG. RESULTS: All patients had initial neutrophil and platelet engraftment. Secondary graft failure was observed in 2 (6%) patients receiving myeloablative HSCT and 3 (23%) patients receiving RIC. At a median follow up of 64 months (13-108), 43 of 44 patients are alive. The 5-year probability of overall survival (OS) was 97.8% for all patients, 96.8% for patients received MAC and 100% for patients received RIC. The 5-year probability of thalassemia-free survival was 86.4% for all patients, 90.3% and 77% for patients who received MAC and RIC, respectively. CONCLUSION: Implementing a risk-adopted therapy in patient with thalassemia in Jordan can result in an excellent thalassemia free and OS, especially in those at highest risk.
Subject(s)
Graft Survival , Hematopoietic Stem Cell Transplantation , Tissue Donors , Transplantation Conditioning/methods , beta-Thalassemia/mortality , beta-Thalassemia/therapy , Adolescent , Adult , Antilymphocyte Serum/administration & dosage , Busulfan/administration & dosage , Child , Child, Preschool , Cyclophosphamide/administration & dosage , Disease-Free Survival , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Rejection/mortality , Graft Rejection/therapy , Humans , Immunologic Factors/administration & dosage , Infant , Male , Myeloablative Agonists/administration & dosage , Retrospective Studies , Risk Factors , Survival Rate , Transplantation, Homologous , Vidarabine/administration & dosage , Vidarabine/analogs & derivativesABSTRACT
INTRODUCTION: Cytomegalovirus (CMV) reactivation and infection are well-recognized complications after allogeneic stem cell transplantation (SCT). Only a few studies have addressed CMV reactivation after autologous SCT (ASCT). METHODS: We retrospectively reviewed medical records of 210 adult patients who underwent ASCT for lymphoma or multiple myeloma (MM) at a single center from January 1(st), 2007 until December 31(st), 2012. All patients were monitored weekly with CMV antigenemia test till day 42 after transplantation, and for 2 months after last positive test in those who had any positive CMV antigenemia test before day 42. RESULTS: Thirty-seven (17.6%) patients had CMV reactivation; 23 patients had lymphoma while 14 had MM as the underlying disease. There was no difference in the rate of CMV reactivation between lymphoma and MM patients (20% versus 14.7%, P = 0.32). The majority of the patients were treated with ganciclovir/valganciclovir, all patients had their reactivation resolved with therapy, and none developed symptomatic CMV infection. None of the patients who died within 100 days of transplantation had CMV reactivation. Log-rank test showed that CMV reactivation had no effect on the overall survival of patients (P values, 0.29). CONCLUSION: In our cohort, CMV reactivation rate after ASCT was 17.6%. There was no difference in reactivation rates between lymphoma and MM patients. With the use of preemptive therapy, symptomatic CMV infection was not documented in any patient in our cohort. CMV reactivation had no impact on patients' survival post ASCT.
Subject(s)
Antineoplastic Agents/administration & dosage , Multiple Myeloma , Adult , Aged , Antineoplastic Agents/adverse effects , Autografts , Disease-Free Survival , Female , Follow-Up Studies , Humans , Jordan/epidemiology , Male , Middle Aged , Multiple Myeloma/mortality , Multiple Myeloma/therapy , Survival RateABSTRACT
BACKGROUND: Control of blood pressure remains suboptimal worldwide. High rates of undiagnosed and untreated hypertensive patients raise the need of searching for the basis of this situation among prescribing physicians. AIM: To evaluate the awareness of medical residents and practicing physicians in Jordan about the treatment of high blood pressure according to the seventh report of the Joint National Committee (JNC VII). METHOD: A written questionnaire was distributed to 200 physicians from different areas of Jordan during the period from November 2005 till February 2006. Recruitment of physicians in this study was in general, military, private hospitals and in clinics. A rigorously developed questionnaire on changes seen in JNC VII, target blood pressure goals, and the treatment of high blood pressure options was administered by trained medical personnel. RESULTS: One hundred and forty five physicians (72.5%) consented to complete the questionnaire. The practices of recent graduates from medical school were not better than those of older graduates. As a general rule, physicians in Jordan under treat high blood pressure. CONCLUSION: Our findings highlight the need for the revision of the teaching curricula in medical schools with regard to the management of hypertension, as well as the initiation of a widespread and intensive continuing medical education for all physicians involved in the management of patients with hypertension. Particular efforts are needed to encourage the use of low-cost thiazides and the use of angiotension converting enzyme inhibitors in heart failure patients and other compelling indications.